Valneva IPO Presentation Deck
VLA15: Development Outlook
■ Phase 2 trial (VLA15-221) in adults and pediatric subjects initiated¹
Trial to include participants from 5-65 years of age and a reduced immunization
schedule (Month 0-6 compared to Month 0-2-6)
The trial triggered a milestone payment of $10 million, upon dosing of the first
subject, from Pfizer to Valneva
Initial pediatric population data expected in Q2 2022¹
VLA15-221 will also investigate a booster dose of VLA15, administered one year
following the six Month dose¹
V
■ Phase 3 pivotal efficacy trial planned to commence pending positive readout
from VA15-221 in 2022¹
Clinical readout, based on one tick season, projected end 2023
■ Subject to regulatory approval first licensure anticipated H1 2025
1Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate
Valneva - Roadshow Presentation
April 2021
14View entire presentation